The Society of NeuroInterventional Surgery (SNIS) 13th Annual Meeting sees Codman Neuro announcing that it has entered into an agreement with InNeuroCo, Inc. for exclusive U.S. and European distribution rights for intermediate catheters that enable minimally invasive treatment of hemorrhagic stroke.

Background

The American Stroke Association estimates 3 to 5 million people in the United States have some form of brain aneurysm, though most do not produce any symptoms. However, between 0.5 and 3 percent of people with the condition may suffer from bleeding and rupture and require treatment, which is where interventional devices from specialist neurovascular companies like Codman Neuro step in. And if the company doesn’t have a device of its own to address a particular application, it’s very likely to fill it with a distribution agreement with another specialist company, as is the case here. InNeuroCo, Inc. is a privately held, Florida-based company that develops and manufactures neurovascular products for hemorrhagic stroke (aneurysms).

Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, will be distributing the InNeuroCo Intermediate Catheter (IC) and the InNeuroCo Super Distal Access (SDA) device under the terms of this newly announced agreement. The InNeuroCo IC, which has already received regulatory approval in the U.S. and Europe, has shown optimized tracking during insertion. The InNeuroCo SDA is pending U.S. FDA 510 (k) clearance. The catheters will be offered alongside the full line of Codman Neuro microcatheters and guiding catheters, which support the delivery of neurovascular products including the CODMAN ENTERPRISE® 2 Vascular Reconstruction Device.

Company comments

“Intermediate catheters are increasingly used by neurovascular specialists to facilitate the delivery of other devices, including stents and thrombectomy devices for the treatment of stroke,” said P. Laxmin Laxminarain, Worldwide President of Codman Neuro. “This agreement with InNeuroCo demonstrates our commitment to neurovascular care and will help us strengthen our access portfolio and our ability to provide a total solution in this fast growing market.”